Senate Bill, 89th Legislature, Regular Session (2025)
SB 2308
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Filed by Sen. Parker (R).
How far it got in 2025
Became law
Last official action June 11, 2025.
Who testified
Who signed up to testify at each committee hearing, and where they stood, from the committee's official witness list.
Senate Health & Human Services, April 23, 2025
Official witness list11 for, 0 against, 0 on3 spoke at the hearing; the rest registered a position or sent written testimony. “On” means neither for nor against, often an agency answering questions.
Organizations represented (8)
- Breakthrough Therapies Initiativeregistered lobby clientfor
- Meadows Mental Health Policy Institutefor
- National Association of Social Workers- Texas Chapterfor
- REID Foundation and American Ibogaine Initiativefor
- Texans For Greater Mental Healthregistered lobby clientfor
- Texas Chapter American College of Physiciansfor
- Texas Medical Associationregistered lobby clientfor
- VETS: Veterans Exploring Treatment Solutionsfor
3 people representing themselves
For (3): Luttrell, Marcus; Crumpton, Sam; Deline, Steven
Names appear as printed on the official list. “Registered lobby client” means the organization's name matches a client in 2025 lobby registrations filed with the Texas Ethics Commission; organizations whose names are spelled differently there aren't marked.
We keep a summary of each 2025 bill. Its full history, text, amendments, and votes are on Texas Legislature Online.